Thalidomide Survivors Say U.S. Numbers Are Understated

Children born to mothers who were prescribed thalidomide in the United States during the 1950s and 1960s are advocating for increased recognition and support, asserting that the government's count of affected individuals is significantly understated. Thalidomide, a sedative and anti-nausea medication, was administered to pregnant patients without full FDA approval or adequate disclosure of its risks. The drug was later found to cause severe birth defects, including phocomelia, a condition characterized by underdeveloped limbs. While thalidomide was withdrawn from the market in 1962, its legacy continues to affect survivors and their families.

Advocates, such as the Thalidomide Children's Support Group, estimate that the number of U.S. survivors could be in the hundreds, far exceeding official figures. These survivors and their families often face ongoing medical, physical, and financial challenges stemming from the birth defects. They are calling for greater transparency from government agencies, including the Food and Drug Administration (FDA), regarding the drug's historical distribution and the extent of its impact. The group is also pushing for improved access to specialized healthcare, financial assistance, and public acknowledgment of their experiences.

The historical context reveals that thalidomide was approved for use in West Germany in 1957 and subsequently marketed in over 50 countries. In the United States, however, it was never formally approved by the FDA for general sale. Despite this, it was available through investigational new drug programs and was sometimes prescribed off-label. Dr. Frances Kelsey, an FDA reviewer, famously resisted approving thalidomide in the U.S. due to safety concerns, a decision that is credited with preventing a widespread tragedy on American soil comparable to that in other nations. Nevertheless, some exposure did occur within the U.S., leading to the birth of children with deformities.

Survivors and their families are now seeking to ensure that their stories are not forgotten and that they receive the necessary resources to manage their long-term health needs. This includes advocating for legislative changes that could provide ongoing support and compensation. The movement aims to bring attention to the ethical failures in drug approval processes of the past and to highlight the enduring impact of such decisions on individuals and families. The call for recognition extends beyond mere acknowledgment, seeking tangible improvements in the quality of life for those affected by thalidomide exposure.